ChemotherapyFDA-approvedFirst-line
Azacitidine
How it works
Interferes with DNA synthesis, preventing cancer cell growth and division.
Cancer types
Leukemia— MDS
Efficacy
Studies show that azacitidine can induce complete or partial response in approximately 50% of patients with MDS.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Q702 with Azacitidine and Venetoclax for Leukemia | Leukemia | phase-1 | — | Source → |
| New Treatment Combination for Newly Diagnosed Acute Myeloid Leukemia | Leukemia | phase-3 | — | Source → |
| Comparing Treatments for Newly Diagnosed AML Patients | Leukemia | phase-2 | — | Source → |
| New Study Examines Ivosidenib and Azacitidine for AML Patients | Leukemia | phase-3 | — | Source → |
| Testing Azacitidine and Abatacept in T-Cell Lymphoma | Leukemia | phase-1 | — | Source → |
| Axatilimab and Azacitidine Trial for Advanced Blood Cancers | Leukemia | phase-1 | — | Source → |
| Testing Azacitidine and Gemtuzumab Ozogamicin in Older Adults with Untreated Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Azacitidine Helps Some Patients with Blood Cancer Avoid Relapse | Leukemia | phase-2 | 60 (63%) patients were relapse free 6 months after azacitidine initiation. | Source → |
| New Treatment Combination Shows Promise for CML Patients | Leukemia | phase-2 | The patients who underwent transplantation had a 50% 3-year probability of survival compared with 18% for nontransplanted patients. | Source → |
| Lab Study Finds New Way to Monitor Azacitidine Treatment in Leukaemia | Leukemia | lab-study | — | Source → |
| Combining PD-1 Inhibitor and Azacitidine for Relapsed Leukemia | Leukemia | phase-2 | The overall response rate after one cycle of the treatment was 75.0% (15/20), and 35.0% (7/20) of the patients achieved complete remission or complete remission with incomplete hematologic recovery after two cycles of the treatment. | Source → |
| Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia | Leukemia | observational | Rates of real-world relapse-free survival and overall survival at 12 months from oral-AZA initiation were 66.9% and 74.5%, respectively. | Source → |
| Azacitidine Therapy in Elderly AML Patients | Leukemia | phase-3 | — | Source → |
| Long-term response to azacitidine in T-cell leukemia relapse | Leukemia | observational | — | Source → |
| Combining Venetoclax and Azacitidine Treats Some Relapsed Acute Myeloid Leukemia Patients | Leukemia | phase-2 | 22.2% of patients in the group achieved complete remission or complete remission with incomplete blood count recovery. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.